Breast Cancer
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC699 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer (AC699-001)
- Details
ClinicalTrials.gov ID:
NCT05654532
Diagnosis Type:
NA
USOR Number:
- Address
,
P: